MV BioTherapeutics SA news
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022.
The presentation has been included in stream A titled &ldqu
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant.
Malcisbo and MV Bio have previously
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021.
The presentation has been included in the morning str
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners.
Please contact
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies.
“We weren’t sure about the potential success when we applied to the Swiss Pavillon wi
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the
We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV).
“During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original live attenuated microbial vaccines, which were exemplified as microvaccines&
T cell dependent secretory IgA (SIgA) generated in the Peyer’s patches (PPs) of the small intestine shapes a broadly diverse microbiota that is crucial for host physiology.
The mutualistic co-evolution of host and microbes led to the relative tolerance of host’s immune system towards commensal microorganisms.
The ATP-gated ionotropic P2X7 receptor limits T follicular helper (Tfh) cells expansion and germinal center (GC) reaction in the PPs.
MicroVaccines SA (from now on “MV”) has been officially incorporated in Canton Ticino on October 26th, 2018 as a spin-off of the Institute for Research in Biomedicine (from now on “IRB”) by Dr. Fabio Grassi, M.D., Ph.D.
“This is an incredible achievement for a researcher and M.D., whose ambition is to translate experimental findings to medical application” says Dr. Fabio Grassi, founder and Chairman of MV.
“The technology